Stryker Corporation (SYK) fundamentals: P/E, valuation, undervalued?
Stryker Corporation · Health Care · ref. ETF XLV · price $282.55
In short — Stryker Corporation trades at 29.3× earnings (P/E), 16.9× forward, with a net margin of 14.4 % and revenue growth of +9 %. Read: Cheap for the growth (P/E 17 for ~44% growth (PEG 0.4)).
Is Stryker Corporation stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$282.55-23.6% over range
Oct 14, 25low $269.75 · high $388.35Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
82% recommend buying · 17 analysts
Valuation : Cheap for the growth — P/E 17 for ~44% growth (PEG 0.4)
Valuation
29.3
P/E (price/earnings)
16.9
Forward P/E
0.66
PEG
4.5
Price/book (P/B)
$108.4B
Market cap
9.65
EPS
Profitability & growth
14.4 %
Net margin
+9 %
Revenue growth
+44 %
Earnings growth
$15.4B
Total debt
Stryker Corporation income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $18.4B | $2.4B | 12.8 % |
| 2023 | $20.5B | $3.2B | 15.4 % |
| 2024 | $22.6B | $3.0B | 13.2 % |
| 2025 | $25.1B | $3.2B | 12.9 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Stryker Corporation's P/E and is the stock undervalued? What's a good P/E?
Stryker Corporation's P/E is 29.3 (forward 16.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Stryker Corporation profitable?
Stryker Corporation has a net margin of 14.4 % (EPS 9.65). The company is profitable.
Is SYK stock expensive?
Our read: "Cheap for the growth" — P/E 17 for ~44% growth (PEG 0.4). Cross-check with growth and sector.
💬 A question about Stryker Corporation? The JPI assistant answers using our backtest data.